A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR Study

Trial Profile

A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR Study

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Sunitinib (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms STELLAR
  • Most Recent Events

    • 31 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 03 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 Jun 2017.
    • 30 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top